Lil­ly says about 70% of pa­tients tak­ing tirzepatide ex­pe­ri­enced an ad­verse event

Eli Lil­ly shared more de­tailed da­ta about its GIP/GLP-1 re­cep­tor ag­o­nist tirzepatide on Thurs­day at the Eu­ro­pean As­so­ci­a­tion for the Study of Di­a­betes an­nu­al meet­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER